In anti-estrogen-resistant BC, blocking DOT1L affects ERα-dependent transcription, including silencing of ESR1 and FOXA1 genes, with a consequent inhibitory effect on tumor growth both in vitro and in vivo88. This evidence concerns the gene ESR1 and breast cancer.